| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 241 | Compositions and methods of formulation for enteral formulas containing sialic acid | US10413508 | 2003-04-14 | US20040202765A1 | 2004-10-14 | Robert J. McMahon; Mary Frances Locniskar; Steven Charles Rumsey; Joshua C. Anthony; Ratchapong Wungtanagorn |
| A nutritionally complete infant formula containing sialic acid derived from one or a number of nutritionally appropriate sources is described. | ||||||
| 242 | Method to alter the isomeric profile of trans fatty acid in ruminant meat and milk and to increase the concentration of $I(cis)-11 conjugated linoleic acid | US10450632 | 2004-01-22 | US20040116513A1 | 2004-06-17 | Yvan Larondelle; Michel Focant; Eric Mignolet; Juha Mikko Griinari |
| The present invention relates to methods for altering the fatty acid composition in milk or tissue fat directly derived from a milk producing ruminant The methods consist of administering to said milk producing ruminant a suitable amount of a chemical compound selected from the vitamin E family, or a structurally or functionally related compound or derivative thereof. At high doses, vitamin E influences ruminal biohydrogenation and allows the production of milk or tissue fat with a highly desirable fatty acid profile: high trans-11 C18:1, high cis-9, trans-11 C18:02 (CLA), low trans-10 C18:1. Methods are disclosed to obtain said desirable fatty acid profile, thereby improving the nutritional benefits to human health associated with CLA. Milk and tissue fat obtained by said methods are also disclosed. Dietary intakes of cis-9, trans-11 C18:2 CLA and trans-11 C18:1 fatty acids in milk or meat, or products thereof, produced in accordance with the present invention in ruminant animals, can be effective in preventing cancer in different sites, reduce risk of coronary heart disease and to enhance immune function. | ||||||
| 243 | Mutated recombinant collagens | US08278774 | 1994-07-22 | US06653450B1 | 2003-11-25 | Richard A. Berg; Paul David Toman; Donald G. Wallace |
| The invention provides recombinant procollagen chains having a natural collagen chain separated from one or two propeptides by one or two non-natural site-specific proteolytic agent (e.g., protease) recognition sites. A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used: the selection of particular site-specific proteolytic agent/recognition site pairs is based on the conformation of the resulting procollagen, the availability of the site-specific proteolytic agent, the compatibility of the proteolysis with production of mature collagen, among other factors. Recombinant collagens chains are produced by contacting the subject recombinant procollagen chains with the appropriate site-specific proteolytic agents. Nucleic acids encoding the subject procollagen chains operably linked to transcription regulatory elements are used in vectors and cells for the production of recombinant collagen. Such collagen is used in tissue and cell cultureware and therapeutically, such as in biodegradable surgical materials and for tissue augmentation. | ||||||
| 244 | Methods of incorporating polyunsaturated fatty acids in milk | US10312106 | 2003-03-28 | US20030211221A1 | 2003-11-13 | Jesus R. Abril; William R Barclay; Archimede Mordenti; Marco Tassinari; Alessandro Zotti |
| Method for incorporating polyunsaturated fatty acids into milk with improved efficiency. The methods include protecting the polyunsaturated fatty acids, including omega-3 and omega-6 polyunsaturated fatty acids, with a protective agent prior to feeding the fatty acids to a milk producing animal. Methods for feeding polyunsaturated fatty acids to milk producing animals by top dressing a polyunsaturated fatty acid supplement on top of animal feed compositions and methods of making and using such compositions are also provided. | ||||||
| 245 | Cow milk with enhanced nutritive and health values | US09311948 | 1999-05-14 | US06602537B1 | 2003-08-05 | Kenneth R. Cummings; Donald L. Palmquist |
| A cow milk product with enhanced nutritional and health values for human consumption, obtained from cows fed with a feedstock having a supplement containing at least about 60 weight percent of calcium oleate, which product has milk fat with a profile of fat constituents including about 1-3.5 weight percent of conjugated linoleic acid, about 2-6 weight percent of trans-11 18:1 fatty acid, about 20-30 weight percent of cis-9 18:1 fatty acid, and about 30-38 weight percent of 14:0 and 16:0 fatty acid, per total milk fat, and wherein the 18:1 to 18:0 fatty acid ratio in the milk fat is about 2-3.2:1. | ||||||
| 246 | Lysosomal proteins produced in the milk of transgenic animals | US09516332 | 2000-03-01 | US20030097665A1 | 2003-05-22 | Arnold J.J. Reuser; Ans T. Van der Ploeg; Frank R. Pieper; Martin Ph. Verbeet |
| The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6null position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy. | ||||||
| 247 | New use of ammonium compounds and/or urea | US09987558 | 2001-11-15 | US20030021856A1 | 2003-01-30 | Lars Wiklund |
| The use of a physiologically innocuous ammonium compound and/or urea as an additive to an infant formula or a pap or for the preparation of a pharmaceutical composition for the prophylaxis of sudden infant death syndrome (SIDS) is disclosed as is also, an infant formula or a pap which in addition to conventional ingredients contains a physiologically innocuous ammonium compound an/or urea. Furthermore, a method of preventing SIDS is disclosed, which method comprises administering to the infant an infant formula or a pap as indicated above, and a method for prophylaxis of SIDS, wherein a pharmaceutical composition containing a physiologically innocuous ammonium compound and/or urea is administered to the infant or the appropriately selected or modified non-pathogenic, urease-producing bacteria are supplied to the gastrointestinal tract of the infant. Finally, a method for the diagnosis of the risks for SIDS is disclosed according to which method the faeces of the infant are analyzed with respect to the presence of urea, urease activity and/or ammonium ions, the presence of urea, the absence of abnormally low urease activity and ammonium ion, respectively, indicating risks for SIDS. | ||||||
| 248 | Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected | US10207709 | 2002-07-25 | US20030017250A1 | 2003-01-23 | Robert B. Elliott; Jeremy P. Hill |
| The invention is based on the discovery that certain variants of null-casein may induce Type-1 diabetes in susceptible individuals while other variants do not. The invention consists of the selection of non-diabetogenic milk producing cows and recovering and processing their milk and milk products. Another aspect of the invention is selectively breeding cows which produce the non-diabetogenic milk. | ||||||
| 249 | L-carnitine agent | US09923849 | 2001-08-07 | US06472011B1 | 2002-10-29 | Takafumi Yakabe; Kiyoko Ozaki; Masaharu Shimatani; Tadashi Idota |
| An L-carnitine agent has an indispensable function in the body and utility as a material for pharmaceutical agents or food and drink. By subjecting milk or modified milk products of mammals from which casein is removed, to the treatment of desalting and partial removal of lactose followed by drying, L-carnitine content, lactose content, and ash content are adjusted to 0.1˜100 mmol/100 g, 20˜95 g/100 g, and 5 g/100 g or less, respectively. | ||||||
| 250 | Fermentation process for producing long chain omega-3 fatty acids with euryhaline microorganisms | US09461709 | 1999-12-14 | US06451567B1 | 2002-09-17 | William R. Barclay |
| A process is provided for growing the microflora Thraustochytrium, Schizochytrium, and mixtures thereof, which includes the growing of the microflora in fermentation medium containing non-chloride containing sodium salts, in particular sodium sulfate. In a preferred embodiment of the present invention, the process produces microflora having a cell aggregate size useful for the production of food products for use in aquaculture. Further disclosed is a food product which includes Thraustochytrium, Schizochytrium, and mixtures thereof, and a component selected from flaxseed, rapeseed, soybean and avocado meal. Such a food product includes a balance of long chain and short chain omega-3 highly unsaturated fatty acids. Further, a process for producing lipids includes a fermentation by growing euryhaline microorganisms which are capable of producing 1.08 grams per liter of the fermentation medium per day of long chain omega-3 fatty acids per 40 grams of sugar per liter of the fermentation medium at a sodium ion concentration of 60% seawater. The lipids are then extracted from the euryhaline microorganisms. | ||||||
| 251 | Compositions and methods for treating enzyme deficiency | US09770496 | 2001-01-29 | US20020013953A1 | 2002-01-31 | Arnold J. Reuser; Ans T. Van der Ploeg; Martin Ph. Verbeet |
| The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, methods of generating the same, pharmaceutical compositions for use in enzyme replacement therapy, and methods of treating Pompe's disease using human acid alpha glucosidase. | ||||||
| 252 | Transgenic non-human mammal expressing the DNA sequence encoding kappa casein mammary gland and milk | US08256799 | 1994-12-06 | US06222094B1 | 2001-04-24 | Lennart Hansson; Mats Strömqvist; Sven Bergström; Olle Hernell; Jan Törnell |
| The present invention relates to an expression system comprising a DNA sequence encoding a polypeptide which ha a biological activity of human &kgr;-casein, the system comprising a 5′-flanking sequence capable of mediating expression of said DNA sequence. In preferred embodiments the 5′-flanking sequence is from a milk protein gene of a mammal such as a casein gene or whey acidic protein (WAP) gene and the DNA sequence contains at least one intron sequence. The invention further relates to DNA sequences, replicable expression vectors and cells harboring said vectors, recombinant polypeptide e.g. in glycosylated form, and milk, infant formula or nutrient supplement comprising recombinant polypeptide. The invention also relates to a method for producing a transgenic non-human mammal comprising injecting an expression system as defined above and optionally a further DNA encoding &bgr;-casein or an analog, variant or subsequence thereof into a fertilized egg or a cell of an embryo of a mammal so as to incorporate the expression system into the germline of the mammal and developing the resulting injected fertilized egg or embryo into an adult female mammal. In one embodiment, the endogenous polypeptide expressing capability of the mammal is destroyed and/or replaced with the expression system defined above. The invention further relates to a transgenic non-human mammal such as a mouse, rat, rabbit, goat, sheep, pig, lama, camel or bovine species whose germ cells a somatic cells contain a DNA sequence as defined above as a result of chromosomal incorporation into the non-human mammalian genome, or into the genome of an ancestor of said non-human mammal. | ||||||
| 253 | Compositions for inhibiting dental caries and/or middle ear infections and uses thereof | US68393 | 1998-08-24 | US6143330A | 2000-11-07 | Antti Sakari Aaltonen; Jouko Suhonen |
| Compositions for treating or preventing dental caries and/or middle ear infections. These compositions comprise antibodies to dental caries and/or antibodies to bacteria causing middles ear infections and/or an agent preventing the adhesion, accumulation or reporduction of the pathogens of tooth or middle ear. The preferred agent is xylitol. Methods for using these compositions are also included. | ||||||
| 254 | Lysosomal proteins produced in the milk of transgenic animals | US700760 | 1996-07-29 | US6118045A | 2000-09-12 | Arnold J. J. Reuser; Ans T. Van der Ploeg; Frank R. Pieper; Martin Ph. Verbeet |
| The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6' position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy. | ||||||
| 255 | Complete nutritional milk compositions and products | US448231 | 1999-11-24 | US6093425A | 2000-07-25 | A. Reza Kamarei |
| Complete nutritional milk compositions and products such as unflavored and flavored milks, yogurts, ice creams and frozen yogurts can be prepared through pasteurization, ultra-pasteurization or sterilization processes. By varying the choice and quantity of nutritional and functional ingredients, compositions which include a milk comprise, per serving size: from about 0.1% to about 80% of the daily value of Sodium, Potassium, and vitamin A; from about 0.1% to about 250% of the daily value of Vitamin C; and from about 0.1% to about 80% of the daily value of calcium, iron, vitamin D, vitamin E, vitamin K, Thiamine, Riboflavin, Niacin, vitamin B6, Folate, vitamin B12, Biotin, Pantothenic acid, Phosphorus, Iodine, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, and Chloride; wherein the percent daily value (D.V.) is based on a 2,000 calorie diet. | ||||||
| 256 | Morphogenic protein compositions of matter | US889419 | 1997-07-08 | US6071708A | 2000-06-06 | William K. Jones; Ronald F. Tucker; David C. Rueger; Hermann Oppermann; Engin Ozkaynak; Thangavel Kuberasampath |
| Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies. | ||||||
| 257 | Production of recombinant polypeptides by bovine species and transgenic methods | US158313 | 1998-09-21 | US6066725A | 2000-05-23 | Herman A. DeBoer; Rein Strijker; Herbert L. Heyneker; Gerard Platenburg; Sang He Lee; Frank Pieper; Paul J. A. Krimpenfort |
| Transgenes for producing recombinant polypeptides transgenic bovine species are described. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk. The invention also includes transgenic bovine species capable of producing recombinant polypeptides in transgenic milk as well as the milk from such transgenic bovine species and food formulations containing one or more recombinant polypeptide. | ||||||
| 258 | Healthy baby infant formula beverage and healthy baby toddler formula beverage | US696655 | 1996-08-14 | US6063433A | 2000-05-16 | Marguerite F. Benward; Wallace Benward |
| A beverage mixture for infants and toddlers containing goat milk, rice milk and aloe vera juice and distilled water which is free of refined sugar and cow milk. | ||||||
| 259 | Transgenic bovines and milk from transgenic bovines | US464167 | 1995-06-05 | US6013857A | 2000-01-11 | Herman A. Deboer; Rein Strijker; Herbert L. Heyneker; Gerard Platenburg; Sang He Lee; Frank Pieper; Paul J. A. Krimpenfort |
| Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk. The invention also includes transgenic bovine species capable of producing recombinant polypeptides in transgenic milk as well as the milk from such transgenic bovine species and food formulations containing one or more recombinant polypeptide. Methods are also provided for producing transgenic non-human mammals having a desirable phenotype. The method comprises first methylating a transgene followed by introduction into fertilized oocytes. The oocytes are then cultured to form pre-implantation embryos. Thereafter, at least one cell is removed from each of the pre-implantation embryos and the DNA digested with a restriction endonuclease capable of cleaving the methylated transgene but incapable of cleaving the unmethylated form of the transgene. Those pre-implantation embryos which have integrated the transgene contain DNA which is resistant to cleavage by the restriction endonuclease in the region containing the transgene. | ||||||
| 260 | Production of human recombinant collagen in the milk of transgenic mammals | US473465 | 1995-06-07 | US5962648A | 1999-10-05 | Richard A. Berg |
| Production of human procollagen or collagen in cells which ordinarily do not produce these molecules is effected by constructing expression systems compatible with mammary glands of non-human mammals. For example, expression systems can be microinjected into fertilized oocytes and reimplanted in foster mothers and carried to term in order to obtain transgenic non-human mammals capable of producing milk containing recombinant human procollagen or collagen. Human procollagen or collagen produced in this manner can be made of a single collagen type uncontaminated by other human or non-human collagens. | ||||||
QQ群二维码
意见反馈
意见反馈